Abstract |
Pruritus is a common and disabling symptom for patients undergoing hemodialysis. Many topical and systemic treatments have been used for uremic pruritus, mostly in anecdotal reports. A recent case series demonstrated that topical tacrolimus ointment 0.03% had a significant antipruritic effect for patients with uremia. In an attempt to confirm these findings, we conducted a randomized, double-blind, vehicle-controlled study to assess the efficacy of tacrolimus ointment 0.1% for the treatment of hemodialysis-related pruritus. The results of this study do not demonstrate that tacrolimus ointment 0.1% is more effective than vehicle in relieving uremic pruritus.
|
Authors | Maria I Duque, Gil Yosipovitch, Alan B Fleischer Jr, Joy Willard, Barry I Freedman |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 52
Issue 3 Pt 1
Pg. 519-21
(Mar 2005)
ISSN: 1097-6787 [Electronic] United States |
PMID | 15761435
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunosuppressive Agents
- Ointments
- Tacrolimus
|
Topics |
- Administration, Topical
- Aged
- Double-Blind Method
- Humans
- Immunosuppressive Agents
(administration & dosage, therapeutic use)
- Middle Aged
- Ointments
- Pruritus
(drug therapy, etiology)
- Renal Dialysis
(adverse effects)
- Tacrolimus
(administration & dosage, therapeutic use)
- Uremia
(complications)
|